Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-07-19

FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)

View source ↗

Summary

FDA approved a supplemental application for COPAXONE (glatiramer acetate) by Teva Neuroscience, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • COPAXONE (GLATIRAMER ACETATE)

Snippet

SUPPL AP for COPAXONE (GLATIRAMER ACETATE)